Israeli Ministry of Health approves Raphael Pharma's Phase IIa COVID-19 trial for cannabis-based drug

Raphael Pharmaceutical Inc.

Israeli Ministry of Health approved Raphael Pharmaceutical's application to commence a Phase IIa clinical trial in COVID-19 patients.
The trial protocol was approved by the Helsinki Committee at Rambam Hospital on December 8, 2022.
The trial involves a cannabis-based drug aimed at mitigating deterioration in COVID-19 patients.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.